Affymetrix

Affymetrix was a pioneering company in the field of biotechnology, renowned for developing and commercializing DNA microarray technology. Its flagship GeneChip platform enabled high-throughput analysis of gene expression and genetic variation, revolutionizing genomics research and molecular diagnostics. The company played a critical role in the Human Genome Project and became a major supplier to academic, pharmaceutical, and clinical laboratories worldwide before its acquisition by Thermo Fisher Scientific.

● Introduction

Affymetrix was instrumental in transforming genomics from a low-throughput science into a data-rich, industrial-scale endeavor. Its core innovation was the GeneChip, a type of DNA microarray that utilized photolithography—a technique borrowed from the semiconductor industry—to synthesize hundreds of thousands of oligonucleotide probes on a silicon wafer. This technology allowed scientists to simultaneously measure the expression levels of tens of thousands of genes or to scan an individual's genome for millions of single-nucleotide polymorphisms. The company's products were widely adopted in basic research, drug discovery, and the development of personalized medicine, making it a central player in the biotechnology landscape of the late 1990s and 2000s.

● History

The company's origins trace back to work by Stephen Fodor and his colleagues at the Affymax research institute in the late 1980s, where they conceptualized using photolithography for combinatorial chemistry. In 1992, Fodor co-founded Affymetrix with John R. Stuelpnagel and others, securing initial funding from venture capital firms like Glaxo and H&Q Healthcare Investors. A landmark achievement came in 1996 with the launch of the first commercial GeneChip, designed for studying HIV mutations. The company's initial public offering in 1996 was highly successful, capitalizing on the fervor surrounding the Human Genome Project. Throughout the 2000s, Affymetrix expanded its portfolio through strategic acquisitions, including Genetic MicroSystems and ParAllele BioScience, solidifying its position in genotyping and clinical diagnostics before facing increased competition from next-generation sequencing technologies.

● Products and Services

Affymetrix's product line centered on its proprietary GeneChip platform and the associated scanner and software systems for data analysis. Key product families included expression arrays like the Human Genome U133 Plus 2.0 Array, genotyping arrays such as the Genome-Wide Human SNP Array 6.0, and cytogenetics arrays for detecting chromosomal abnormalities. The company also offered whole-transcriptome analysis kits and provided extensive bioinformatics support and assay services through its certified laboratories. These tools were essential for research in institutions like the National Institutes of Health and pharmaceutical companies including Pfizer and Merck & Co., enabling studies in cancer genomics, pharmacogenomics, and agricultural biotechnology.

● Technology

The technological cornerstone was the GeneChip, manufactured using a process akin to that for making computer chips. Photolithography masks and ultraviolet light were used to direct the synthesis of specific DNA sequences directly on a coated quartz substrate. This in situ fabrication allowed for extremely high probe density and reproducibility. Each chip contained millions of features, with each feature housing millions of copies of a specific oligonucleotide probe. For analysis, fluorescently labeled cDNA or cRNA samples were hybridized to the array, and a specialized confocal scanner measured fluorescence intensity. Sophisticated algorithms from packages like Expression Console and Genotyping Console converted this raw data into biological information, a process that set industry standards for microarray data analysis.

● Applications

Affymetrix technology found broad application across the life sciences. In academic research, it was used for gene expression profiling to identify genes involved in diseases like Alzheimer's disease and diabetes mellitus. Within pharmaceutical companies, it facilitated target identification and toxicogenomics studies. In clinical settings, its arrays were employed for prenatal testing to detect copy-number variations and in oncology for tumor subclassification. The technology also supported large-scale genome-wide association studies, such as those conducted by the Wellcome Trust Case Control Consortium, which linked genetic variants to conditions like Crohn's disease and rheumatoid arthritis. Furthermore, it was used in agricultural research by entities like Monsanto for crop improvement.

● Acquisitions and Merger

To expand its technological capabilities and market reach, Affymetrix pursued an aggressive acquisition strategy. Key purchases included Genetic MicroSystems in 2000, enhancing its scanner manufacturing, and ParAllele BioScience in 2005, acquiring key genotyping technology. It also bought USB's biochemicals unit and Panomics, adding assay tools for pathway analysis. In the diagnostics arena, it acquired Eureka Genomics and formed partnerships with Roche Diagnostics. Facing market pressure from Illumina and the rise of next-generation sequencing, Affymetrix agreed to be acquired by Thermo Fisher Scientific in 2016 for approximately $1.3 billion, a deal that integrated its microarray business into the larger life sciences conglomerate.

Category:Biotechnology companies of the United States Category:Companies based in Santa Clara County, California Category:Defunct biotechnology companies